My ePortfolio Register   

WIN Symposium 2017 /
DNA damage response inhibition

26th - 27th Jun 2017

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 04.07.17
Views: 563

Dr Giorgio Massimini - Vice President, Head of Early Clinical Oncology, Merck, Darmstadt, Germany

Dr Massimini speaks with ecancer at WIN 2017 about novel drugs suitable as monotherapy or in combination to inhibit DNA repair pathways in tumours.

He highlights VX970 / M6620, a novel drug affecting the ATR kinase pathway of DNA repair, as well as M3814 which is currently in assessment combined with radiotherapy, and considers class-associated toxicities of DNA repair pathway inhibition.


Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence